Skip to main content
Erschienen in: Spektrum der Augenheilkunde 1/2018

12.10.2017 | Vitreoretinal Disorders and Vitrectomy

Differential diagnosis of neovascular age-related macular degeneration

Multimodal imaging features and practical implications of distinguishing types 1, 2, and 3

verfasst von: Michael Engelbert, MD, PhD

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Summary

The differential diagnosis of neovascular age-related macular degeneration (NVAMD) has practical implications because type 1 neovascularization (NV) with or without polypoidal components, type 2 NV, and type 3 NV (also called “retinal angiomatous proliferation”), differ in regard to visual prognosis, propensity for development of geographic atrophy, as well as frequency of antiangiogenic treatment and optimal dosing strategies. In many instances, only a combination of various imaging techniques facilitates the distinction between NVAMD variants, thereby permitting individualized therapy. Ideally, this allows for the use of a minimum number of treatments to achieve an anatomically and visually optimal outcome.
Literatur
1.
Zurück zum Zitat Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333–49.CrossRef Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333–49.CrossRef
2.
Zurück zum Zitat Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014;158(4):769–79.CrossRef Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol. 2014;158(4):769–79.CrossRef
3.
Zurück zum Zitat Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148(1):70–8.CrossRef Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. 2009;148(1):70–8.CrossRef
4.
Zurück zum Zitat Blinder KJ, Bradley S, Bressler NM, et al. Treatment of age-related macular degeneration with Photodynamic therapy study group; Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407–18.CrossRef Blinder KJ, Bradley S, Bressler NM, et al. Treatment of age-related macular degeneration with Photodynamic therapy study group; Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003;136:407–18.CrossRef
5.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRef Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRef
6.
Zurück zum Zitat Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRef Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRef
7.
Zurück zum Zitat Rezaei KA, Stone TW, editors. Global trends in retina survey. Chicago: American Society of Retina Specialists; 2014. Rezaei KA, Stone TW, editors. Global trends in retina survey. Chicago: American Society of Retina Specialists; 2014.
8.
Zurück zum Zitat Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular neovascular membranes. Am J Ophthalmol. 1998;126:59–69.CrossRef Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular neovascular membranes. Am J Ophthalmol. 1998;126:59–69.CrossRef
9.
Zurück zum Zitat Freund KB, Engelbert M, Fine HF. Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. Ophthalmic Surg Lasers Imaging Retina. 2015;46:508–12.CrossRef Freund KB, Engelbert M, Fine HF. Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. Ophthalmic Surg Lasers Imaging Retina. 2015;46:508–12.CrossRef
10.
Zurück zum Zitat Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, et al. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014;3(4):111–5.PubMedPubMedCentral Gallego-Pinazo R, Dolz-Marco R, Gómez-Ulla F, et al. Pachychoroid diseases of the macula. Med Hypothesis Discov Innov Ophthalmol. 2014;3(4):111–5.PubMedPubMedCentral
11.
Zurück zum Zitat Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina. 2015;35(2):176–86.CrossRef Xu L, Mrejen S, Jung JJ, et al. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Retina. 2015;35(2):176–86.CrossRef
12.
Zurück zum Zitat Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 2010;30(9):1368–75.CrossRef Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina. 2010;30(9):1368–75.CrossRef
13.
Zurück zum Zitat Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-relatedmacular degeneration. Am J Ophthalmol. 2007;143:566–83.CrossRef Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-relatedmacular degeneration. Am J Ophthalmol. 2007;143:566–83.CrossRef
14.
Zurück zum Zitat Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of Intravitreal anti-vascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–31.CrossRef Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of Intravitreal anti-vascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29:1424–31.CrossRef
Metadaten
Titel
Differential diagnosis of neovascular age-related macular degeneration
Multimodal imaging features and practical implications of distinguishing types 1, 2, and 3
verfasst von
Michael Engelbert, MD, PhD
Publikationsdatum
12.10.2017
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 1/2018
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-017-0374-5

Weitere Artikel der Ausgabe 1/2018

Spektrum der Augenheilkunde 1/2018 Zur Ausgabe

Vitreoretinal Disorders and Vitrectomy

Vitreous and macular hole: genesis and nemesis

Vitreoretinal Disorders and Vitrectomy

Autosomal-dominante Optikusatrophie